Mobile Menu - OpenMobile Menu - Closed

Cummings Criticizes Mylan’s “Discount” for EpiPens

Aug 25, 2016
Press Release

Cummings Criticizes Mylan’s “Discount” for EpiPens


Washington, D.C. (Aug. 25, 2016)—Today, Rep. Elijah E. Cummings, Ranking Member of the House Committee on Oversight and Government Reform, issued the following statement after Mylan announced that, after drastically increasing the price of life-saving EpiPens, the company would offer a discount for a portion of out-of-pocket costs for some individuals:

“Offering a meager discount only after widespread bipartisan criticism is exactly the same tactic used by drug companies across the industry to distract from their exorbitant price increases, as our investigation has shown repeatedly.  Nobody is buying this PR move anymore.  Mylan should not offer after-the-fact discounts only for a select few—it should reverse its massive price increases across the board immediately.  Drug company CEOs are using a corrupt business model to profit off of our most vulnerable citizens and using them like ATMs.  I will continue to fight to ensure that all Americans can afford the drugs they need, and I have requested that the Oversight Committee hold a hearing in September to determine exactly how and why this company drastically raised its prices for this critical medication.”

114th Congress